Related Experiment Video
Updated: Feb 15, 2026

Analysis of SCAP N-glycosylation and Trafficking in Human Cells
Published on: November 8, 2016
On the glycosylation aspects of biosimilarity
László Hajba1, Ákos Szekrényes2, Beáta Borza2
1MTA-PE Translational Glycomics Research Group, Research Institute for Biomolecular and Chemical Engineering, University of Pannonia, Veszprem, Hungary.
Abstract:
The recent expiration of several protein therapeutics opened the door for biosimilar development. Biosimilars are biologic medical products that are similar but not identical copies of already-authorized protein therapeutics. Critical quality attributes (CQA), such as post-translational modifications of recombinant biotherapeutics, are important for the clinical efficacy and safety of both the innovative biologics and their biosimilar counterparts. Here, we summarize biosimilarity CQAs, considering the regulatory guidelines and the statistical aspects (e.g., biosimilarity index) and then discuss glycosylation as one of the important attributes of biosimilarity. Finally, we introduced the 'Glycosimilarity Index', which is based on the averaged biosimilarity criterion.
Related Concept Videos
Protein Glycosylation
Glycosylation occurs in...
Drug Products: Biologics, Biosimilars and Interchangeables
Quantitative Aspects of Drug-Receptor Interaction
Self-Schemas
What is Natural Selection?
Ethics in Research

